Annual report pursuant to Section 13 and 15(d)

Subsequent events (Details)

Subsequent events (Details) - USD ($)
Apr. 15, 2017
Mar. 22, 2017
Mar. 17, 2017
Mar. 01, 2017
Dec. 31, 2016
Subsequent events Details          
Company raised from exercise of warrants into common stock amounted   $ 1,765,733      
Company holds shares in GVS         $ 500,000
GVS shares valued at         $ 50,000
Company invested in GW Pharmaceuticals PLC Common Stock       $ 1,049,086  
Company loaned G Farma an aggregate principal amount Under two secured promissory notes     $ 500,000    
Two promissory notes bearing interest each per annum     7.42%    
The first promissory note amount is for the purchase of real estate $ 120,000        
Monthly payment for real estate property 1,107        
Balloon payment of approximately at maturity for real estate 93,585        
The second promissory note is a working capital loan secured by all assets of G Farma 380,000        
Monthly payment for working capital loan 3,505        
Balloon payment of approximately at maturity for capital loan 296,352        
G Farma stock then outstanding equal to number of shares     1.50%    
Company received in warrant redemption fees from designees for warrants   $ 56,490      
Company will receive a monthly consulting fee in arears per month $ 1,400        
G Farma purchased restricted shares of the Company's Common Stock in a private placement 222,223        
Purchase price of a restricted shares per share value $ 2.25        
An aggregate purchase price restricted shares paid $ 500,002